CEPI provides $30m to advance novel coronavirus vaccine
European Pharmaceutical Review
JULY 11, 2022
These coronavirus RBDs are attached to a nanoparticle by protein tags, enabling the structure to display fragments from multiple viruses on a single nanoparticle. . In May 2020, CEPI invested an additional $384 million to accelerate the development and manufacture of Novavax’s NVX-CoV2373 vaccine. The innovative protein ?“glue”
97 
Let's personalize your content